BrainsWay Valuation Multiples

Discover BrainsWay's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Cerus, Sunmax Biotechnology, MiMedx Group, Tactile Medical and more.

BrainsWay Overview

About BrainsWay

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.


Founded

2006

HQ

Israel

Employees

120

Financials (LTM)

Revenue: $61M
EBITDA: $10M

EV

$570M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

BrainsWay Financials

BrainsWay reported last 12-month revenue of $61M and EBITDA of $10M.

In the same LTM period, BrainsWay generated $46M in gross profit, $10M in EBITDA, and $11M in net income.

Revenue (LTM)


BrainsWay P&L

In the most recent fiscal year, BrainsWay reported revenue of $52M and EBITDA of $10M.

BrainsWay is profitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 19%, and net margin of 15%.

See analyst estimates for BrainsWay
LTMLast FY202320242025202620272028
Revenue$61M$52M$32M$41M$52M
Gross Profit$46M$39M$23M$31M$39M
Gross Margin76%75%74%75%75%
EBITDA$10M$10M($3M)$5M$10M
EBITDA Margin17%19%(8%)13%19%
EBIT Margin13%8%(16%)3%8%
Net Profit$11M$8M($4M)$3M$8M
Net Margin18%15%(13%)7%15%

Financial data powered by Morningstar, Inc.

BrainsWay Stock Performance

BrainsWay has current market cap of $623M, and enterprise value of $570M.

Market Cap Evolution


BrainsWay's stock price is $15.53.

BrainsWay share price increased by 0.8% in the last 30 days, and by 31.1% in the last year.

BrainsWay has an EPS (earnings per share) of $0.19.

See more trading valuation data for BrainsWay
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$570M$623M0.0%0.8%-5.3%31.1%$0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

BrainsWay Valuation Multiples

BrainsWay trades at 9.4x EV/Revenue multiple, and 56.2x EV/EBITDA.

See NTM and 2027E valuation multiples for BrainsWay

EV / Revenue (LTM)


BrainsWay Financial Valuation Multiples

As of July 19, 2026, BrainsWay has market cap of $623M and EV of $570M.

BrainsWay has a P/E ratio of 58.2x.

LTMLast FY202320242025202620272028
EV/Revenue9.4x10.9x17.9x13.9x10.9x
EV/EBITDA56.2x58.1x(222.7x)106.4x58.1x
EV/EBIT72.1x131.9x(115.0x)n/m131.9x
EV/Gross Profit12.4x14.5x24.3x18.6x14.5x
P/E58.2x81.7x(148.5x)213.4x82.3x
EV/FCF-37.6xn/m87.7x37.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified BrainsWay Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

BrainsWay Margins & Growth Rates

BrainsWay grew revenue by 30% and EBITDA by 29% in the last fiscal year.

In the most recent fiscal year, BrainsWay reported gross margin of 75%, EBITDA margin of 19%, and net margin of 15%.

See estimated margins and future growth rates for BrainsWay

BrainsWay Margins

Last FY202420252026202720282029
Gross Margin75%75%75%76%
EBITDA Margin19%13%19%19%
EBIT Margin8%3%8%16%
Net Margin15%7%15%19%
FCF Margin29%16%29%-

BrainsWay Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth30%29%27%30%
Gross Profit Growth31%30%29%31%
EBITDA Growth29%(309%)83%29%
EBIT Growth151%(128%)211%151%
Net Profit Growth73%(170%)159%75%
FCF Growth-(690%)133%-

Data powered by FactSet, Inc. and Morningstar, Inc.

BrainsWay Operational KPIs

BrainsWay's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

BrainsWay's Rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BrainsWay's Rule of X is 95% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for BrainsWay
LTMLast FY202320242025202620272028
Rule of 4044%49%---
Bessemer Rule of X84%95%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue33%36%19%17%15%
G&A Expenses to Revenue12%32%49%35%32%
R&D Expenses to Revenue18%18%21%18%18%
Opex to Revenue-67%89%71%67%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

BrainsWay Competitors

BrainsWay competitors include Cerus, Sunmax Biotechnology, MiMedx Group, Tactile Medical, Cytek Biosciences, Japan Lifeline, Nanosonics, Myriad Genetics, IBA Group and Lumibird.

Most BrainsWay public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cerus2.8x2.6x67.9x42.9x
Sunmax Biotechnology9.7x-17.5x-
MiMedx Group1.2x1.5x4.7x10.5x
Tactile Medical1.7x1.6x12.8x12.0x
Cytek Biosciences1.8x1.8x(546.3x)(68.0x)
Japan Lifeline1.4x1.4x5.9x6.1x
Nanosonics4.0x3.7x24.8x32.3x
Myriad Genetics0.8x0.8x17.2x17.6x

This data is available for Pro users. Sign up to see all BrainsWay competitors and their valuation data.

Start Free Trial

Investments by BrainsWay

BrainsWay has invested in 6 companies to date.

Latest investment by BrainsWay was on May 17th 2026. BrainsWay invested in Hopemark Health in their $2M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by BrainsWay

Hopemark Health
Neurolief
Brainstim Health
Heading Health
Description
Hopemark Health is a psychiatric clinic that offers mental health care, ketamine therapy, and genetic testing services.
Neurolief is an Israel-headquartered neuromodulation company treating mental health and neurological disorders with non-invasive devices. Its platform delivers multi-channel electrical stimulation to key cranial neural pathways simultaneously, modulating brain areas for mood regulation and pain relief. Targeting depression, anxiety, and migraines, the wearable system offers home-based therapy sessions. Neurolief employs neuroscience veterans to refine pulse patterns based on clinical feedback from European and US trials.
BrainStim Health manages clinics delivering neuroplasticity treatments including TMS and ketamine for mental health conditions.
Heading Health is a mental health platform utilizing technology for personalized treatments including Spravato nasal spray, transcranial magnetic stimulation, telepsychiatry sessions, and intramuscular ketamine infusions. The service operates virtual clinics in multiple US states to expand access to evidence-based therapies.
HQ CountryUnited StatesIsraelCanadaUnited States
HQ City
Oak Brook, IL
Netanya
-
Austin, TX
Deal Date17 May 202625 Mar 202619 Feb 202627 Oct 2025
RoundStrategic investmentUndisclosed stageStrategic investmentStrategic investment
Raised$2M$6M$1M$2M
InvestorsBrainsWayBrainsWayBrainsWayBrainsWay
Valuation$3Mundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all BrainsWay investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About BrainsWay

When was BrainsWay founded?BrainsWay was founded in 2006.
Where is BrainsWay headquartered?BrainsWay is headquartered in Israel.
How many employees does BrainsWay have?As of today, BrainsWay has over 120 employees.
Who is the CEO of BrainsWay?BrainsWay's CEO is Hadar Levy.
Is BrainsWay publicly listed?Yes, BrainsWay is a public company listed on Nasdaq.
What is the stock symbol of BrainsWay?BrainsWay trades under BWAY ticker.
When did BrainsWay go public?BrainsWay went public in 2019.
Who are competitors of BrainsWay?BrainsWay main competitors include Cerus, Sunmax Biotechnology, MiMedx Group, Tactile Medical, Cytek Biosciences, Japan Lifeline, Nanosonics, Myriad Genetics, IBA Group, Lumibird.
What is the current market cap of BrainsWay?BrainsWay's current market cap is $623M.
What is the current revenue of BrainsWay?BrainsWay's last 12 months revenue is $61M.
What is the current revenue growth of BrainsWay?BrainsWay revenue growth (NTM/LTM) is 27%.
What is the current EV/Revenue multiple of BrainsWay?Current revenue multiple of BrainsWay is 9.4x.
What is the current EBITDA of BrainsWay?BrainsWay's last 12 months EBITDA is $10M.
What is BrainsWay's EBITDA margin?BrainsWay's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of BrainsWay?Current EBITDA multiple of BrainsWay is 56.2x.
How many companies BrainsWay has acquired to date?BrainsWay hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies BrainsWay has invested to date?As of July 2026, BrainsWay has invested in 6 companies.
What was the last BrainsWay investment?On 17th May 2026 BrainsWay invested in Hopemark Health, participating in a $2M Strategic investment round at $3M valuation.
In what companies BrainsWay invested in?BrainsWay invested in Neurolief, Stella Mental Health, Axis Integrated Mental Health, Hopemark Health, Heading Health, and Brainstim Health.

See public comps similar to BrainsWay

Lists including BrainsWay

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial